Results 1 to 10 of about 83,328 (323)

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. [PDF]

PLoS ONE, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling   +35 more
doaj   +7 more sources

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Journal for ImmunoTherapy of Cancer, 2023
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma.
Celeste Lebbe, Parminder Singh, Omid Hamid, Frances A Collichio, Igor Puzanov, Merrick Ross, Theodore Logan, Philip Friedlander, Claus Garbe, Janice M Mehnert, John Glaspy, Axel Hauschild, Wendy Snyder, Jason A Chesney, Mohammed M Milhem, Harshada Joshi   +15 more
doaj   +2 more sources

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
Multiple treatments of unresectable advanced or metastatic melanoma have been licensed in the adjuvant setting, causing tremendous interest in developing neoadjuvant strategies for melanoma.
Mingyi Jing, Mingyi Jing, Yi Cai, Jing Shi, Xufan Zhang, Baohua Zhu, Baohua Zhu, Fan Yuan, Fan Yuan, Jie Zhang, Jie Zhang, Min Xiao, Mingling Chen   +12 more
doaj   +1 more source

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

BMC Cancer, 2021
Background Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking.
Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen, Andriy Moshyk, Srividya Kotapati, Mark R. Middleton   +18 more
doaj   +1 more source

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +12 more sources

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

Journal of Skin Cancer, 2021
Background. Checkpoint inhibitors are effective in the treatment of several types of cancer, either being used separately or in combination. Ipilimumab pioneered the treatment of metastatic melanoma, and nowadays, it has been used more frequently in ...
A. A. Formozo, J. R. Gomes, R. A. Schmerling, A. C. Buzaid   +3 more
doaj   +1 more source

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma

Cancer Medicine, 2021
Background Adjuvant ipilimumab was found to improve the overall survival and reduce toxicity compared to high‐dose interferon (HDI) in patients with resected, high‐risk melanoma. However, the cost of ipilimumab is substantially higher than HDI.
Mia Salans, Patrick Travis Courtney, Anthony Yip, James D. Murphy   +3 more
doaj   +1 more source

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

CPT: Pharmacometrics & Systems Pharmacology, 2020
Ipilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time‐varying clearance (CL) was
Kinjal Sanghavi, Jason Zhang, Xiaochen Zhao, Yan Feng, Paul Statkevich, Jennifer Sheng, Amit Roy, Heather E. Vezina   +7 more
doaj   +1 more source

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

Cancer Medicine, 2023
Background The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns ...
Brandon Lu, Wei Fang Dai, Ruth Croxford, Wanrudee Isaranuwatchai, Jaclyn Beca, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan   +12 more
doaj   +1 more source

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

World Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang   +10 more
doaj   +1 more source